6 most recent filings and news items mentioning REPL. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/REPL/news?limit=20"
Pull REPL filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayRepligen CEO Olivier Loeillot highlights Bio-Life's industry leadership and outlines the integration of their cell processing operations, targeting a fourth-quarter closing.
View filing at SEC.gov →Market-Moving News for July 31st
View filing at SEC.gov →RP1's IGNYTE study efficacy results were deemed evaluable and clinically meaningful by the FDA's Cell, Tissue, and Gene Therapies Advisory Committee. The favorable outcome is a key regulatory milestone as the company awaits an August 2 action date.
View filing at SEC.gov →9 Health Care Stocks With Whale Alerts In Today’s Session
View filing at SEC.gov →Replimune announced fiscal 2026 financial results and confirmed the FDA accepted its resubmission of the BLA for RP1 in combination with nivolumab for advanced melanoma with a goal date set for August 2026. This regulatory milestone, combined with strong clinical data presentatio
View filing at SEC.gov →Replimune announced it will resubmit its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma following productive FDA discussions, with the agency committing to prioritize review. The development signals regulatory progress for the company's
View filing at SEC.gov →